Clinical Cancer Research, Vol 1, Issue 4 369-376, Copyright © 1995 by American Association for Cancer Research

Mutagenic activity of topoisomerase I inhibitors

H Hashimoto, S Chatterjee and NA Berger
Departments of Medicine, Biochemistry, and Cancer Center, Case Western Reserve University, School of Medicine, Cleveland, Ohio 44106-4937, USA.

Topoisomerase I-directed agents are now in Phase I and II clinical trials and show great promise as potentially important agents for cancer chemotherapy. Because of their mechanism of action they may also be potential mutagens; however, their mutagenicity and oncogenicity still remain to be elucidated. We have previously shown that VP-16, a topoisomerase II-directed agent, induces sister chromatid exchanges and gene deletions and/or rearrangements in vitro. These observations may account for both the cytotoxic effects of topoisomerase II-directed agents as well as their recently reported leukemonogenic potential. To evaluate the potential mutagenicity of topoisomerase I-directed drugs, we measured mutant frequencies at the hypoxanthine phosphoribosyl transferase locus of the V79 Chinese hamster fibroblast cell line treated with the topoisomerase I-directed drugs camptothecin and topotecan, and compared these results with mutant frequency obtained with the topoisomerase II-directed drug VP-16 and an alkylating agent, N-methyl-N'-nitro-N-nitrosoguanidine (MNNG). All of these drugs showed a dose-dependent increase in mutant frequency at the hypoxanthine phosphoribosyl transferase locus. At a dose producing approximately 30% survival, VP-16, camptothecin, and topotecan induced mutant frequencies of 11.3 x 10(-6), 4.9 x 10(-6), and 2.7 x 10(-6), respectively, whereas the spontaneous mutant frequency at this locus was 0.3 x 10(-6). In contrast, the alkylating agent MNNG produced a mutant frequency of 562 x 10(-6) at 26% survival dose. The molar mutagenic potencies, expressed as mutant frequency/mol-h exposure, for VP-16, camptothecin, topotecan, and MNNG at approximately 30% survival dose were 0.9, 8.2, 2.3, and 56.8, respectively. On Southern blot analysis after EcoRI, PstI, or HindIII digestion, 6 of 12 independent thioguanine-resistant mutants induced by topotecan showed gene deletions or rearrangements. In contrast, five of five independent spontaneous mutants and six of six independent mutants induced by MNNG demonstrated the same restriction pattern as the parental V79 cells. These results indicate that the mutant frequency and the mutagenic potential of topoisomerase I and II active agents are quantitatively similar. The results further demonstrate that topoisomerase I and II active agents introduce mutations characterized by gene deletions and rearrangements, whereas spontaneous mutations and those induced by alkylating agents appeared to be more characteristically associated with point mutations. Thus, clinical use of the topoisomerase I and II active agents is expected to cause similar mutagenic effects that could potentially lead to secondary malignancies.

This article has been cited by other articles:

				Y. Merrouche, F. Mugneret, and J.-Y. Cahn Secondary acute promyelocytic leukemia following irinotecan and oxaliplatin for advanced colon cancer Ann. Onc., June 1, 2006; 17(6): 1025 - 1026. [Full Text] [PDF]

				B. A. Carneiro, L. Kaminer, M. Eldibany, C. Sreekantaiah, K. Kaul, and G. Y. Locker Oxaliplatin-related acute myelogenous leukemia. Oncologist, March 1, 2006; 11(3): 261 - 262. [Abstract] [Full Text] [PDF]

				S. El-Hizawi, J. P. Lagowski, M. Kulesz-Martin, and A. Albor Induction of Gene Amplification as a Gain-of-Function Phenotype of Mutant p53 Proteins Cancer Res., June 1, 2002; 62(11): 3264 - 3270. [Abstract] [Full Text] [PDF]

				K. S. Cunha, M. L. Reguly, U. Graf, and H. H. Rodrigues de Andrade Comparison of camptothecin derivatives presently in clinical trials: genotoxic potency and mitotic recombination Mutagenesis, March 1, 2002; 17(2): 141 - 147. [Abstract] [Full Text] [PDF]

				C. H. Takimoto, G. Morrison, N. Harold, M. Quinn, B. P. Monahan, R. A. Band, J. Cottrell, A. Guemei, V. Llorens, H. Hehman, et al. Phase I and Pharmacologic Study of Irinotecan Administered as a 96-Hour Infusion Weekly to Adult Cancer Patients J. Clin. Oncol., February 1, 2000; 18(3): 659 - 659. [Abstract] [Full Text] [PDF]